No. It is a small-molecule mitochondrial uncoupler, but it is commonly sold by research-chemical vendors that also carry peptides.

How is it different from DNP?

Both uncouple mitochondria, but BAM-15 is reported in preclinical studies to have a wider safety window and not to depolarize the plasma membrane at effective doses.

Has it been tested in humans?

Evidence is largely preclinical and based on animal models; it has not been validated as a human therapeutic.

← All peptides

Weight & Metabolic

Preclinical

BAM-15

Also known as: BAM-15

A small-molecule mitochondrial protonophore (uncoupler) studied as a metabolic compound for fat loss and metabolic health. It is not a peptide but is commonly sold alongside research peptides.

Mechanism of Action

BAM-15 is a mitochondrial uncoupler that dissipates the proton gradient across the inner mitochondrial membrane, partially decoupling electron transport from ATP synthesis. This increases substrate oxidation and energy expenditure as heat rather than ATP. Unlike the older uncoupler DNP, BAM-15 is reported to have a wider safety window and does not depolarize the plasma membrane at effective concentrations. In rodent studies it reduced adiposity and improved insulin sensitivity without raising body temperature in the way DNP does.

Half-life: Several hours in rodent pharmacokinetic studies
Administration Routes: oral, subcutaneous
Research Status: Preclinical